Current therapeutic strategies for inflammation following traumatic spinal cord injury

Neural Regeneration Research

Volumn 7, Issue 23, 2012, Pages 1812-1821

  Singh, Priyanka L ^a,b   Agarwal, Nitin ^a,b   Barrese, James C ^a   Heary, Robert F ^a,b  

^a New Jersey Medical School   (United States)

^b Reynolds Family Spine Laboratory   (United States)

Author keywords

Acute spinal cord injury; Erythropoietin; Estrogen; Etanercept; Hypothermia; Inflammation; Neuroprotective; Rolipram; Secondary injury; Treatment

Indexed keywords

EID: 84891611719     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374     Document Type: Article

References (60)

1. National Spinal Cord Injury Statistical Center. Spinal Cord Injury Facts and Figures at a Glance. The University of Alabama at Birmingham. Birmingham. https://www.nscisc.uab.edu/public_content/pdf/Facts%202011%20Feb%20Final.pdf. Accessed June 15, 2011.
2. Dawodu ST. Spinal Cord Injury-Definition, Epidemiology, Pathophysiology. Medscape Reference. http://emedicine.medscape.com/article/322480-overview. Accessed June 6, 2011.
3. Fu ES, Saporta S. Methylprednisolone inhibits production of interleukin-1beta and interleukin-6 in the spinal cord following compression injury in rats. J Neurosurg Anesthesiol. 2005;17(2):82-85.
4. Bracken MB, Shepard MJ, Hellenbrand KG, et al. Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J Neurosurg. 1985;63(5):704-713.
5. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322(20):1405-1411.
6. Miller SM. Methylprednisolone in acute spinal cord injury: a tarnished standard. J Neurosurg Anesthesiol. 2008; 20(2):140-142.
7. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA. 1997;277(20): 1597-1604.
8. Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg. 2000;93(1 Suppl):1-7.
9. Dietrich WD, Cappuccino A, Cappuccino H. Systemic hypothermia for the treatment of acute cervical spinal cord injury in sports. Curr Sports Med Rep. 2011;10(1):50-54.
10. Levi AD, Casella G, Green BA, et al. Clinical outcomes using modest intravascular hypothermia after acute cervical spinal cord injury. Neurosurgery. 2010;66(4): 670-677.
11. Lo TP Jr, Cho KS, Garg MS, et al. Systemic hypothermia improves histological and functional outcome after cervical spinal cord contusion in rats. J Comp Neurol. 2009;514(5):433-448.
12. Dietrich WD. Therapeutic hypothermia for acute severe spinal cord injury: ready to start large clinical trials? Crit Care Med. 2012;40(2):691-692.
13. Rabchevsky AG, Patel SP, Springer JE. Pharmacological interventions for spinal cord injury: Where do we stand? How might we step forward? Pharmacol Ther. 2011; 132(1):15-29.
14. Wells JE, Hurlbert RJ, Fehlings MG, et al. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain. 2003;126(Pt 7):1628-1637.
15. Casha S, Zygun D, McGowan MD, et al. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain. 2012;135(4): 1224-1236.
16. Tohda C, Kuboyama T. Current and future therapeutic strategies for functional repair of spinal cord injury. Pharmacol Ther. 2011;132(1):57-71.
17. Matis GK, Birbilis TA. Erythropoietin in spinal cord injury. Eur Spine J. 2009;18(3):314-323.
18. Gensel JC, Donnelly DJ, Popovich PG. Spinal cord injury therapies in humans: an overview of current clinical trials and their potential effects on intrinsic CNS macrophages. Expert Opin Ther Targets. 2011;15(4):505-518.
19. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000; 97(19):10526-10531.
20. Boran BO, Colak A, Kutlay M. Erythropoietin enhances neurological recovery after experimental spinal cord injury. Restor Neurol Neurosci. 2005;23(5-6):341-345.
21. Fumagalli F, Madaschi L, Brenna P, et al. Single exposure to erythropoietin modulates Nerve Growth Factor expression in the spinal cord following traumatic injury: comparison with methylprednisolone. Eur J Pharmacol. 2008;578(1):19-27.
22. Samantaray S, Sribnick EA, Das A, et al. Neuroprotective efficacy of estrogen in experimental spinal cord injury in rats. Ann N Y Acad Sci. 2010;1199:90-94.
23. Smith JA, Das A, Butler JT, et al. Estrogen or estrogen receptor agonist inhibits lipopolysaccharide induced microglial activation and death. Neurochem Res. 2011; 36(9):1587-1593.
24. Cuzzocrea S, Genovese T, Mazzon E, et al. Effect of 17beta-estradiol on signal transduction pathways and secondary damage in experimental spinal cord trauma. Shock. 2008;29(3):362-371.
25. Sribnick EA, Samantaray S, Das A, et al. Postinjury estrogen treatment of chronic spinal cord injury improves locomotor function in rats. J Neurosci Res. 2010;88(8): 1738-1750.
26. Sribnick EA, Wingrave JM, Matzelle DD, et al. Estrogen attenuated markers of inflammation and decreased lesion volume in acute spinal cord injury in rats. J Neurosci Res. 2005;82(2):283-293.
27. Samantaray S, Matzelle DD, Ray SK, et al. Physiological low dose of estrogen-protected neurons in experimental spinal cord injury. Ann N Y Acad Sci. 2010;1199:86-89.
28. Genovese T, Mazzon E, Crisafulli C, et al. Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther. 2006;316(3):1006-1016.
29. Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother. 2010;10(6): 985-1002.
30. Marchand F, Tsantoulas C, Singh D, et al. Effects of Etanercept and Minocycline in a rat model of spinal cord injury. Eur J Pain. 2009;13(7):673-681.
31. Genovese T, Mazzon E, Crisafulli C, et al. Combination of dexamethasone and etanercept reduces secondary damage in experimental spinal cord trauma. Neuroscience. 2007;150(1):168-181.
32. Nikulina E, Tidwell JL, Dai HN, et al. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci U S A. 2004; 101(23):8786-8790.
33. Pearse DD, Pereira FC, Marcillo AE, et al. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med. 2004;10(6): 610-616.
34. Whitaker CM, Beaumont E, Wells MJ, et al. Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neurosci Lett. 2008;438(2):200-204.
35. Koopmans GC, Deumens R, Buss A, et al. Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury. Exp Neurol. 2009;216(2):490-498.
36. Fleming JC, Bao F, Chen Y, et al. Timing and duration of anti-alpha4beta1 integrin treatment after spinal cord injury: effect on therapeutic efficacy. J Neurosurg Spine. 2009; 11(5):575-587.
37. Fleming JC, Bao F, Chen Y, et al. Alpha4beta1 integrin blockade after spinal cord injury decreases damage and improves neurological function. Exp Neurol. 2008;214(2): 147-159.
38. Hausmann ON. Post-traumatic inflammation following spinal cord injury. Spinal Cord. 2003;41(7):369-378.
39. Jones TB, McDaniel EE, Popovich PG. Inflammatorymediated injury and repair in the traumatically injured spinal cord. Curr Pharm Des. 2005;11(10):1223-1236.
40. Hall ED, Braughler JM. Role of lipid peroxidation in post-traumatic spinal cord degeneration: a review. Cent Nerv Syst Trauma. 1986;3(4):281-294.
41. Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol. 2008;209(2): 378-388.
42. Schwartz M. Macrophages and microglia in central nervous system injury: are they helpful or harmful? J Cereb Blood Flow Metab. 2003;23(4):385-394.
43. Elkabes S, DiCicco-Bloom EM, Black IB. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J Neurosci. 1996;16(8):2508-2521.
44. Fleming JC, Norenberg MD, Ramsay DA, et al. The cellular inflammatory response in human spinal cords after injury. Brain. 2006;129(Pt 12):3249-3269.
45. Anderson DK, Saunders RD, Demediuk P, et al. Lipid hydrolysis and peroxidation in injured spinal cord: partial protection with methylprednisolone or vitamin E and selenium. Cent Nerv Syst Trauma. 1985;2(4):257-267.
46. Braughler JM, Hall ED, Means ED, et al. Evaluation of an intensive methylprednisolone sodium succinate dosing regimen in experimental spinal cord injury. J Neurosurg. 1987;67(1):102-105.
47. Hall ED. Neuroprotective actions of glucocorticoid and nonglucocorticoid steroids in acute neuronal injury. Cell Mol Neurobiol. 1993;13(4):415-432.
48. Bracken MB, Collins WF, Freeman DF, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA. 1984;251(1):45-52.
49. Coleman WP, Benzel D, Cahill DW, et al. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord. 2000;13(3): 185-199.
50. Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg. 1998;89(5):699-706.
51. Hadley MN, Walters BC, Grabb PA, et al. Guidelines for the management of acute cervical spine and spinal cord injuries. Clin Neurosurg. 2002;49:407-498.
52. Rozet I. Methylprednisolone in acute spinal cord injury: is there any other ethical choice? J Neurosurg Anesthesiol. 2008;20(2):137-139.
53. Nesathurai S. Steroids and spinal cord injury: revisiting the NASCIS 2 and NASCIS 3 trials. J Trauma. 1998;45(6): 1088-1093.
54. Yu CG, Jimenez O, Marcillo AE, et al. Beneficial effects of modest systemic hypothermia on locomotor function and histopathological damage following contusion-induced spinal cord injury in rats. J Neurosurg. 2000;93(1 Suppl):85-93.
55. Ha KY, Kim YH. Neuroprotective effect of moderate epidural hypothermia after spinal cord injury in rats. Spine (Phila Pa 1976). 2008;33(19):2059-2065.
56. Levi AD, Green BA, Wang MY, et al. Clinical application of modest hypothermia after spinal cord injury. J Neurotrauma. 2009;26(3):407-415.
57. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002;99(14):9450-9455.
58. ClinicalTrials.gov. Evaluation of tolerability and efficacy of erythropoietin (EPO) treatment in spinal shock: comparative study versus methylprednisolone (MP). http://clinicaltrials.gov/ct2/show/NCT00561067.
59. Schowinsky J, Corboy J, Vollmer T, et al. Natalizumabassociated complication? First case of peripheral T cell lymphoma. Acta Neuropathol. 2012;123(5):751-752.
60. Midaglia L, Rodriguez Ruiz M, Muñoz-García D. Severe haematological complications during treatment with natalizumab. Mult Scler. in press.